|Date of first report of the outbreak||
9 May 2017
|Disease or outbreak||
Ebola virus disease (EVD)
|Origin (country, city, region)||
Bas-Uele, Northeast DRC
|Suspected Source (specify food source, zoonotic or human origin or other)||
Zoonotic and human-to-human transmission of Ebola virus (EBOV), subtype Zaire [1-3]
It was unclear how the first deceased victim contracted the virus, but past outbreaks have been linked to consumption of bush meat, especially non-human primates, and direct contact with infected animals .
|Date of outbreak beginning||
Several outbreaks have occurred in different parts of DRC since 2017. The three outbreaks described below are the eighth, ninth and tenth outbreaks of EVD since its discovery in 1976 in the DRC.
2017 Bas-Uélé province outbreak
On 9 May 2017, the World Health Organization (WHO) was informed of a cluster of undiagnosed illness and deaths with haemorrhagic symptoms from 22 April 2017 in Likati health zone, Bas-Uélé province, northern DRC (near the Central African Republic border). Five blood samples were sent to the Institut National de Recherché Biomédicale (INRB) laboratory in Kinshasa, two of which tested positive for EBOV using RT-PCR.
On 11 May 2017, WHO declared the start of the outbreak after being notified by the Ministry of Health (MOH) of DRC of the first two confirmed EVD cases. By then, 9 suspected cases, including 3 deaths, have been reported .
2018 Équateur province outbreak
From 4 April to 9 May 2018, 32 EVD cases (including 18 deaths) were reported from Bikoro health zone, Équateur province, northwest DRC (near the Congo border), approximately 800km southwest of Likati, Bas-Uélé . Five samples were sent to the INRB, two of which tested positive for EBOV using RT-PCR.
On 8 May 2018, WHO declared the start of the outbreak, after being notified by the MOH of DRC of two confirmed EVD cases .
2018 North Kivu province outbreak
On 28 July 2018, the MOH of DRC was informed of a cluster of haemorrhagic fever cases by the North Kivu health division, eastern DRC (near the Uganda border). Mangina, the epicentre of the outbreak , is approximately 700km southeast of Likati, Bas-Uélé and 1,300km east of Bikoro, Équateur . Six blood samples were sent to the INRB laboratory, four of which tested positive for EBOV using GeneXpert-automated PCR.
On 1 August 2018, WHO declared the start of the outbreak after being notified by the Ministry of Health (MOH) of DRC of the four confirmed EVD cases. By 3 August 2018, 43 EVD cases (13 confirmed and 30 probable), including 33 deaths, had been reported in North Kivu province and the neighbouring Ituri province .
|Date outbreak declared over||
For EVD, the end of an outbreak will be declared 42 days (two 21-day incubation cycles of EBOV) after the last confirmed patient of the affected area tested negative for the disease for the second time.
2017 Bas-Uélé province outbreak
On 2 July 2017, WHO declared the end of the outbreak in Bas-Uélé .
2018 Équateur province outbreak
On 24 July 2018, WHO declared the end of the outbreak in Équateur .
2018 North Kivu province outbreak
N/A – ongoing as of 12 May 2019.
|Affected countries & regions||
2017 Bas-Uélé province outbreak
Because of the remote and isolated nature of Likati district, the outbreak was contained within the boundary of Bas-Uélé province. Cases were reported from four health areas:
2018 Équateur province outbreak
Cases were reported from three health areas in Équateur province:
2018 North Kivu province outbreak
As of 12 May 2019, cases were reported from the following 21 health zones:
|Number of cases (specify at what date if ongoing)|
Initial presentation of EVD is non-specific and can be misdiagnosed as other diseases such as malaria, typhoid, and other viral haemorrhagic fevers (including dengue or Lassa fever) .
According to WHO’s case definition, an EVD case is classified as “suspected” if either of the following symptoms applies:
A case is classified as “probable” if it is evaluated by a clinician, or if a diseased patient has an epidemiological link with a confirmed case.
A case is classified as “laboratory confirmed” if a blood sample is tested positive for virus antigen via reverse transcriptase-polymerase chain reaction (RT-PCR) or detection of IgM antibodies directed against EBOV .
For the three outbreaks, cases were alerted to the MOH of DRC by the referral health centre upon showing symptoms of acute haemorrhagic fever. The common symptoms for most of the early cases were high fever and intense fatigue [15-17]. No detailed description was given for any haemorrhagic symptom that accompanies fever (e.g. conjunctival bleeding, gastrointestinal bleeding or bleeding from venipuncture site).
|Mode of transmission (dominant mode and other documented modes)||Bodily fluids contact
Initial transmission of EBOV occurs through contact with an infected animal, such as a fruit bat or a primate. After that, EBOV can be transmitted from human to human via direct contact with blood or bodily fluids (urine, saliva, sweat, faeces, vomit, breast milk and semen) of an infected or deceased person .
The virus can remain in bodily fluids secreted from immunologically privileged sites, including semen, breast milk, ocular fluid and spinal column fluid, even after the infected person has recovered from EVD . However, the amount of viral shedding in each type of fluid is not well quantified .
An infected person can only transmit EBOV once he or she develops signs and symptoms . The incubation period is approximately 2-21 days . Healthcare workers (HCWs) and burial personnel are at high risk of contracting EVD because of close contacts with the infected person and handling of instruments (needles and syringes) containing bodily fluids [22,23]. Hence, infectious control measures in hospitals and safe burial practices are critical in transmission control.
Theoretically, fomite transmission is possible because EBOV was detected in visible dried blood stains  and could persist on glass surface and in the dark for 6 days in a laboratory-controlled setting . However, EBOV does not remain infectious if allowed to dry on environmental surfaces, especially in routinely disinfected wards .
Airborne transmission (aerosol or large droplets)
Experiments have demonstrated transmission of EBOV without direct contact among animals [25,26], suggesting the possibility of transmission via aerosol or large droplets secreted by the infected animal. In mechanically produced aerosols, EBOV was found at sufficient levels to cause lethal infections in primates [27,28]. However, airborne transmission from human to human is uncertain in previous outbreaks . In pathology specimens of the lung, abundant Ebola virus is found , and the Kikwit outbreak in 1995 suggests airborne transmission in at least five cases .
EBOV cannot be transmitted by food (except for consumption of bushmeat in certain parts of the world), mosquito bites, or casual contact with a survivor . However, sexual transmission from recovered survivors and vertical transmission from mother to baby have been documented .
|Demographics of cases||
Demographic details were not available for the 2017 Bas-Uélé province outbreak.
2018 Équateur province outbreak
7 out of 54 reported cases (13%) were HCWs . The median age was 40 years (range 8-80) and 40% were females. 71% of confirmed cases had contact with infected patients, and 58% of confirmed cases attended funerals before the onset of disease .
2018 North Kivu province outbreak
As of 12 May 2019, among 1,705 reported cases, 56% were female, and 29% were children aged less than 18 years. 101 cases (6%) were HCWs .
|Case fatality rate||
2017 Bas-Uélé province outbreak
By 2 July 2017, 4 out of 8 reported cases were fatal. The overall CFR is 50%. The number of fatalities among confirmed cases was not published .
2018 Équateur province outbreak
By 24 July 2018, 33 out of 54 reported cases (17 out of 38 confirmed cases) were fatal. The overall CFR was 61%; the CFR among confirmed cases is 45% .
2018 North Kivu province outbreak
As of 12 May 2019, 1,124 out of 1,705 reported cases (1,036 out of 1,617 confirmed cases) were fatal. The overall CFR is 65.9%; the CFR among confirmed cases is 64.1% .
The initial non-specific presentation of the disease is followed with abdominal pain, severe vomiting and diarrhoea, leading to fluid loss and hypovolemic shock . Patients are also prone to systemic inflammatory response syndrome, characterised by symptoms commonly associated with bacterial sepsis (fever, tachycardia, hyperventilation and leukopenia). Haemorrhage is only observed in a minority of patients .
The combination of hypovolemia, septic shock and haemorrhage eventually results in multi-organ dysfunction, particularly the renal, hepatic and coagulation systems. This happens typically by the second week of the disease and rapidly leads to organ failure and death .
Ebola survivors may develop ocular complications such as uveitis, which can lead to vision loss .
Wearing of personal protective equipment (PPE) can reduce the risk of EBOV transmission by introducing a physical barrier against the infected person’s bodily fluids . However, emphasis on proper donning and doffing technique and double gloving [36,37] is crucial to minimise the risk of self-contamination during removal of PPE .
Several vaccines for EVD are being evaluated in clinical trials [39-42]. One vaccine, called rVSV-ZEBOV, has been demonstrated in phase I-III clinical trials to be safe and immunogenic in humans . This vaccine consists of recombinant vesicular stomatitis virus (VSV) vector expressing a surface glycoprotein from the Zaire Kikwit 1995 strain .
rSVS-ZEBOV is recommended by the Strategic Advisory Group of Experts on Immunization (SAGE) for use against subtype Zaire if no licensed vaccine is available . It was approved for compassionate use by the DRC’s Ethics Committee during the early stage of the 2018 Équateur province and 2018 North Kivu province outbreaks [46-47] based on the genomic analysis of early cases’ pathogen samples .
In May 2019, SAGE recommended an additional vaccine alternative for lower risk individuals, for whom the Ad26.ZEBOV/MVA-BN is being considered . The Ad26.ZEBOV/MVA-BN is a two-dose, multivalent vaccine consisting of an adenovirus-26 vector (Ad26.ZEBOV) and a modified vaccinia Ankara vector (MVA-BN) encoded with Ebola glycoproteins, which have been demonstrated in phase I-II randomised controlled trials (RCT) to be safe and immunogenic for human volunteers [50-51].
Current treatment for EVD is limited to supportive care and symptomatic treatment only. Rehydration via oral or IV route is routinely encouraged to prevent hypovolemic shock. Transfusion of whole blood or coagulation regulators (e.g. clotting factors, fibrinolysis inhibitors, etc.) is administered to counteract haemorrhage. Some patients require anticoagulants to reduce risk of thrombosis and disseminated intravascular coagulation following haemorrhage. Intensive care, including dialysis, hemofiltration, intubation, and mechanical ventilation, is required for patients with multi-organ system failures, but is limited to developed-country settings .
Several experimental therapies are under development, including antivirals, interferons, antibodies and interfering RNA , although none have successfully completed human RCT. There is increasing interest in convalescent therapy, in which patients receive whole blood or plasma from Ebola survivors, which has improved survival rates in past outbreaks . It is recommended by WHO as an interim empirical treatment during outbreaks .
A cocktail of three chimeric monoclonal antibodies, named ZMapp, demonstrated strong antiviral activity in preliminary studies and prevented death even when administered in the late stage of the disease. However, the human RCT (PREVAIL II) only succeeded in demonstrating safety, not efficacy, due to insufficient enrolment .
A phase II-III RCT is underway in the DRC to compare the safety and effectiveness of 3 new therapies against Zmapp: mAb114 (a single monoclonal antibody), remdesivir (an antiviral) and REGN-EB3 (a monoclonal antibody cocktail). The trial is enrolling EBOV patients in Beni, with plans to include patients from other Ebola treatment units .
|Comparison with past outbreaks||
Case fatality rate
The 2018 Équateur province outbreak reported CFR of 61%, which is comparable to previous outbreaks of the same scale, such as the 2014 outbreak (69 cases, CFR 71%) or the 2008 outbreak (32 cases, 47%) .
The 2018 North Kivu province outbreak was the most severe outbreak in the history of the DRC, with 1,705 cases and CFR of 65.9%, which is comparable to other large outbreaks such as the 2007 outbreak (264 cases, 71%) or the 1995 outbreak (315 cases, 79%) .
The 2012 outbreak reported a lower CFR (36 cases, 36%). However, it was caused by a different virus, Bundibugyo ebolavirus .
All three outbreaks were caused by Zaire ebolavirus, which is the causative agent behind the 2014-2016 outbreak in West Africa and all previous outbreaks in the DRC except for the 2012 outbreak [58,60]. Phylogenetic analysis shows that the EBOV strains behind the 2018 Équateur outbreak are genetically linked to the 2014 outbreak, which occurred at the neighbouring Tshuapa province .
Like most previous outbreaks, the Bas-Uélé and Équateur outbreaks were geographically contained due to the remote nature of their epicentres. The Bas-Uélé outbreak’s epicentre is a forested region of Likati health zone, with a population density of only 7 people/km2 . The Équateur outbreak’s epicentre is Bikoro health zone, which is 280km by road from the provincial capital, Mbandaka .
In contrast, the North Kivu outbreak has extended to urban locations, including Beni (population 420,000) and Butembo (population 1 million) [7,63]. It is comparable to the 1995 outbreak in Kikwik (population 500,000) .
Impact on HCWs
This is the first time a vaccination strategy was adopted in the DRC for Ebola response . An extensive ring vaccination campaign with rSVS-ZEBOV has been carried out since August 2018, covering more than 120,000 high-risk individuals, including children, contacts and front-line HCWs. 80% of identified cases (776) had their rings defined and their contacts gave consent for vaccination. 90% of consented contacts were vaccinated, indicating high coverage . Acceptance of vaccination among families and HCWs is high .
To date, Merck & Co. has shipped 100,0000 rSVS-ZEBOV doses to the DRC and agreed to maintain a global emergency stockpile of 300,000 doses. However, in view of the scale of recent Ebola outbreaks, an option to increase the stockpile may be revisited in the future .
By 12 May 2019, over 93,400 contacts have been registered, 14,459 were under surveillance, and 114,498 contacts have been vaccinated with rSVS-ZEBOV . In April 2019, WHO published preliminary results from the observational study of this campaign, claiming an overall vaccine efficacy of 97.5% (95% CI 95.8-98.5%). Out of all vaccinated contacts, 71 contracted EBOV (0.076%). The report concludes that ring vaccination with rSVS-ZEBOV demonstrates protective effects on secondary degree contacts and lowers fatality rate among those contracting EBOV (CFR was 16% among those contracting within 9 days post-vaccination and 0% among those contracting 10 days or more post-vaccination) .
However, despite unprecedented advancements in vaccines, diagnostics, experimental treatment and accumulated institutional experience, the response strategies that were successful in containing the Équateur outbreak failed to replicate the same result in the North Kivu outbreak. Since October 2018, new clusters continue to emerge in multiple health zones .
Genome sequencing confirmed that the two EBOV strains behind the outbreaks in Équateur and North Kivu provinces are genetically distinct. The 2018 Équateur strain is genetically closer to the 2014 outbreak that hit the neighbouring Tshuapa province . On the other hand, samples from Mangina and Beni (2018-2019 North Kivu outbreak) are genetically closer to the sample from Likati (2017 Bas Uélé outbreak) .
The three EBOV strains seem to be independent lineages diverging from a single clade in 1976-1977 (the first Ebola outbreak in the DRC) . This raises the possibility of a single origin reservoir that has been propagating EVD across geographic distances in the DRC, either through habitat fragmentation or migration. A similar hypothesis emerged for the 2014 outbreak, in which bats were identified as the main zoonotic reservoir of EBOV and their spatial-temporal migration patterns were said to correlate with hot spots of EVD outbreaks in West Africa .
Persistence of the outbreak
The current North Kivu-Ituri outbreak is characterised as a complex humanitarian emergency because efforts to contain the outbreak were hampered by a multitude of interlinked issues.
Viral persistence – A possible mechanism for perpetual flare-ups?
Despite having declared the end of the Ebola outbreak in March 2015, Liberia still faced several flare-ups throughout 2015 that were from persistently infected survivors, instead of an active reservoir . Another phylogenetic investigation showed that a female EVD survivor from the 2014 Liberia outbreak might have transmitted EBOV to her son one year later . These examples raised the question of whether persistently affected survivors are a source of unidentified transmission chains in the DRC outbreaks. However, this hypothesis is challenged by the fact that the DRC was not the main affected area in 2014 and does not have a large number of survivors present, compared to Sierra Leone, Liberia and Guinea.
One important link to consider is sexual transmission. Several flare-ups from Liberia, Guinea and Sierra Leone were attributed to sexual intercourse with persistently infected male survivors [83-84]. Serological and genomic data from EVD male survivors demonstrated persistence of viral RNA in semen [85-86] that lasted beyond the WHO-defined waiting period for declaring a country to be free from EVD . This opens up another avenue for community health education: safe sex practices such as sexual abstinence or condom use must be included in the community education package for contacts of EVD survivors .
Why have multiple, genetically distinct outbreaks arisen in the DRC within a period of 24 months?
How can socio-political barriers to disease control be best addressed?
How effective are vaccination campaigns in reducing the spread of the disease in the 2018 North Kivu outbreak, and have cases occurred in vaccinated contacts?
How long will the immunity last among vaccinated people?
How should vaccines be given in view of heightened risk of outbreak expansion? Should the current ring vaccination strategy be replaced by geographical vaccination, covering areas of high population density?
1. Ebola virus disease – Democratic Republic of the Congo: Disease outbreak news – 13 May 2017 [Internet]. WHO; 2017. Retrieved from: https://www.who.int/csr/don/13-may-2017-ebola-drc/en
2. Ebola virus disease – Democratic Republic of the Congo: External Situation Report 3 [Internet]. WHO; 2018. https://apps.who.int/iris/bitstream/handle/10665/272607/SITREP-EVD-DRC-20180518.pdf
3. Epidemiological situation in the province of North Kivu [Internet]. MOH of DRC; 2018. https://us13.campaign-archive.com/?u=89e5755d2cca4840b1af93176&id=2caaec594a
4. Alexander K, Sanderson C, Marathe M, Lewis B, Rivers C, Shaman J et al. What factors might have led to the emergence of Ebola in West Africa?. PLOS Neglected Tropical Diseases. 2015;9(6):e0003652. DOI: http://dx.doi.org/10.1371/journal.pntd.0003652
5. A free and customizable map of the 26 new provinces of the DRC (Democratic Republic of Congo) [Internet]. Comersis.com, c2019 [updated 13 Jan 2019]. Retrieved from: https://map.comersis.com/carte-Democratic-Republic-of-Congo-new-provinces-map-cm20639a160.html
6. Ebola virus disease – Democratic Republic of the Congo: Disease outbreak news – 10 May 2018 [Internet]. WHO; 2018. https://www.who.int/csr/don/10-may-2018-ebola-drc/en
7. New Ebola outbreak declared in North Kivu [Internet]. Médecins Sans Frontières (MSF) International; 05 Sep 2018. Retrieved from: https://www.msf.org/new-ebola-outbreak-declared-north-kivu
8. Ebola virus disease – Democratic Republic of the Congo: Disease outbreak news – 4 August 2018 [Internet]. WHO; 2018. https://www.who.int/csr/don/4-august-2018-ebola-drc/en
9. End of the most recent Ebola outbreak in the Democratic Republic of Congo [Internet]. WHO; 2017. https://www.who.int/emergencies/ebola-DRC-2017/en
10. Ebola virus disease – Democratic Republic of the Congo: External Situation Report 17 [Internet]. WHO; 2018. https://apps.who.int/iris/bitstream/handle/10665/273348/SITREP_EVD_DRC_20180725-eng.pdf
11. Ebola virus disease – Democratic Republic of the Congo: External Situation Report 28 [Internet]. WHO; 2017. http://apps.who.int/iris/bitstream/10665/255793/1/EbolaDRC-30062017.pdf
12. Ebola virus disease – Democratic Republic of the Congo: External Situation Report 41 [Internet]. WHO; 2019. https://apps.who.int/iris/bitstream/handle/10665/312376/SITREP_EVD_DRC_20190514-eng.pdf
13. West T, von Saint André-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Annals of the American Thoracic Society. 2014;11(9):1341-1350. DOI: http://dx.doi.org/10.1089/hs.2018.0056
14. Interim guideline: Case definition recommendations for Ebola or Marburg virus diseases [Internet]. WHO; 2014. https://apps.who.int/iris/bitstream/handle/10665/146397/WHO_EVD_CaseDef_14.1_eng.pdf
15. Ebola virus disease – Democratic Republic of the Congo: External Situation Report 1 [Internet]. WHO; 2017. https://apps.who.int/iris/bitstream/handle/10665/255419/EbolaDRC-1552017-eng.pdf
16. Barry A, Ahuka-Mundeke S, Ali Ahmed Y, Allarangar Y, Anoko J, Archer B et al. Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April–May, 2018: An epidemiological study. The Lancet. 2018;392(10143):213-221. DOI: http://dx.doi.org/10.1016/S0140-6736(18)31387-4
17. Ebola virus disease – Democratic Republic of the Congo: External Situation Report 1 [Internet]. WHO; 2018. https://apps.who.int/iris/bitstream/handle/10665/273640/SITREP_EVD_DRC_20180807-eng.pdf
18. Transmission | Ebola Haemorrhagic Fever [Internet]. CDC [accessed 26 May 2019]. Retrieved from: https://www.cdc.gov/vhf/ebola/transmission/index.html
19. Chughtai A, Barnes M, MacIntyre C. Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control. Epidemiology and Infection. 2016;144(8):1652-1660. DOI: http://dx.doi.org/10.1017/s0950268816000054
20. Bausch D, Towner J, Dowell S, Kaducu F, Lukwiya M, Sanchez A et al. assessment of the risk of Ebola virus transmission from bodily fluids and fomites. The Journal of Infectious Diseases. 2007;196(s2):S142-S147. DOI: http://dx.doi.org/10.1086/520545
21. WHO Ebola Response Team. Ebola Virus Disease in West Africa — The first 9 months of the epidemic and forward projections. New England Journal of Medicine. 2014;371(16):1481-1495. DOI: http://dx.doi.org/10.1056/NEJMoa1411100
22. Coltart C, Johnson A, Whitty C. Role of healthcare workers in early epidemic spread of Ebola: policy implications of prophylactic compared to reactive vaccination policy in outbreak prevention and control. BMC Medicine. 2015;13(1). DOI: http://dx.doi.org/10.1186/s12916-015-0477-2
23. Dowell S, Mukunu R, Ksiazek T, Khan A, Rollin P, Peters C. Transmission of Ebola haemorrhagic fever: a study of risk factors in family members, kikwit, Democratic Republic of the Congo, 1995. The Journal of Infectious Diseases. 1999;179(s1):S87-S91. DOI: http://dx.doi.org/10.1086/514284
24. Sagripanti J.L., Rom A.M., Holland L.E. Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces. Archives of Virology. 2010;155:2035–2039. DOI: http://dx.doi.org/10.1007/s00705-010-0791-0
25. Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. The Lancet. 1995;346(8991-8992):1669-1671. DOI: http://dx.doi.org/10.5555/uri:pii:S0140673695928413
26. Weingartl H, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. Transmission of Ebola virus from pigs to non-human primates. Scientific Reports. 2012;2(1). DOI: http://dx.doi.org/10.1038/srep00811
27. Piercy T, Smither S, Steward J, Eastaugh L, Lever M. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. Journal of Applied Microbiology. 2010;109(5):1531-9. DOI: http://dx.doi.org/10.1111/j.1365-2672.2010.04778.x
28. Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. International Journal of Experimental Pathology. 1995;76(4):227–236
29. Vetter P, Fischer W, Schibler M, Jacobs M, Bausch D, Kaiser L. Ebola virus shedding and transmission: review of current evidence. Journal of Infectious Diseases. 2016;214(suppl 3):S177-S184. DOI: http://dx.doi.org/10.1093/infdis/jiw254
30. Martines R, Ng D, Greer P, Rollin P, Zaki S. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. The Journal of Pathology. 2014;235(2):153-174. DOI: http://dx.doi.org/10.1002/path.4456
31. Roels T, Bloom A, Buffington J, Muhungu G, Mac Kenzie W, Khan A et al. Ebola haemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: Risk factors for patients without a reported exposure. The Journal of Infectious Diseases. 1999;179(s1):S92-S97. DOI: http://dx.doi.org/10.1086/514286
32. MacIntyre C, Chughtai A. Recurrence and reinfection – a new paradigm for the management of Ebola virus disease. International Journal of Infectious Diseases. 2016;43:58-61. DOI: http://dx.doi.org/10.1016/j.ijid.2015.12.011
33. Fletcher T, Fowler R, Beeching N. Understanding organ dysfunction in Ebola virus disease. Intensive Care Medicine. 2014;40(12):1936-1939. DOI: http://dx.doi.org/10.1007/s00134-014-3515-1
34. Yeh S, Shantha J, Hayek B, Crozier I, Smith J. Clinical manifestations and pathogenesis of uveitis in Ebola virus disease survivors. Ocular Immunology and Inflammation. 2018;26(7):1128-1134. DOI: http://dx.doi.org/10.1080/09273948.2018.1484493
35. Verbeek J, Mihalache R. More PPE protects better against Ebola. American Journal of Infection Control. 2016;44(6):731. DOI: http://dx.doi.org/10.1016/j.ajic.2015.12.024
36. Fischer W, Weber D, Wohl D. Personal protective equipment: Protecting health care providers in an Ebola outbreak. Clinical Therapeutics. 2015;37(11):2402-2410. DOI: http://dx.doi.org/10.1016/j.clinthera.2015.07.007
37. Personal protective equipment in the context of filovirus disease outbreak response [Internet]. WHO; 2015. Retrieved from: http://apps.who.int/iris/bitstream/10665/137410/1/WHO_EVD_Guidance_PPE_14.1_eng.pdf
38. MacIntyre C, Chughtai A, Seale H, Richards G, Davidson P. Uncertainty, risk analysis and change for Ebola personal protective equipment guidelines. International Journal of Nursing Studies. 2015;52(5):899-903. DOI: http://dx.doi.org/10.1016/j.ijnurstu.2014.12.001
39. Pavot V. Ebola virus vaccines: Where do we stand?. Clinical Immunology. 2016;173:44-49. DOI: http://dx.doi.org/10.1016/j.clim.2016.10.016
40. Zhu F, Hou L, Li J, Wu S, Liu P, Zhang G et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. 2015;385(9984):2272-2279. doi:10.1016/S0140-6736(15)60553-0
41. Milligan I, Gibani M, Sewell R, Clutterbuck E, Campbell D, Plested E et al. Safety and immunogenicity of novel Adenovirus type 26– and modified vaccinia Ankara–vectored Ebola vaccines. JAMA. 2016;315(15):1610. doi:10.1001/jama.2016.4218
42. Ebola vaccines, therapies, and diagnostics [Internet]. WHO [accessed 26 May 2019]. Retrieved from: https://www.who.int/medicines/emp_ebola_q_as/en/
43. Suder E, Furuyama W, Feldmann H, Marzi A, de Wit E. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. Human Vaccines & Immunotherapeutics. 2018;14(9):2107-2113. DOI: http://dx.doi.org/10.1080/21645515.2018.1473698
44. Regules J, Beigel J, Paolino K, Voell J, Castellano A, Hu Z et al. A recombinant vesicular stomatitis virus Ebola vaccine. New England Journal of Medicine. 2017;376(4):330-341. DOI: http://dx.doi.org/10.1056/NEJMoa1414216
45. Meeting of the Strategic Advisory Group of Experts (SAGE) on immunization, April 2017: Conclusions and recommendations. WHO Weekly Epidemiological Record. 2017;92(22):301-320
46. WHO supports Ebola vaccination of high risk populations in the Democratic Republic of the Congo [Internet]. WHO; 2018. Retrieved from: https://www.who.int/news-room/detail/21-05-2018-who-supports-ebola-vaccination-of-high-risk-populations-in-the-democratic-republic-of-the-congo
47. Ebola vaccination begins in North Kivu [Internet]. WHO; 2018. Retrieved from: https://www.who.int/news-room/detail/08-08-2018-ebola-vaccination-begins-in-north-kivu
48. Mbala-Kingebeni P, Aziza A, Di Paola N, Wiley M, Makiala-Mandanda S, Caviness K et al. Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. The Lancet Infectious Diseases. 2019; DOI: http://dx.doi.org/10.1016/S1473-3099(19)30118-5
49. Interim recommendations on vaccination against Ebola virus disease (EVD) [Internet]. WHO SAGE; 2019. https://www.who.int/immunization/policy/position_papers/interim_ebola_recommendations_may_2019.pdf
50. Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D et al. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. The Journal of Infectious Diseases. 2019. DOI: http://dx.doi.org/10.1093/infdis/jiz071
51. Milligan I, Gibani M, Sewell R, Clutterbuck E, Campbell D, Plested E et al. Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines. JAMA. 2016;315(15):1610. DOI: http://dx.doi.org/10.1001/jama.2016.4218
52. Clark D, Jahrling P, Lawler J. Clinical management of filovirus-infected patients. Viruses. 2012;4(9):1668-1686. DOI: http://dx.doi.org/10.3390/v4091668
53. Interim guidance: Potential Ebola therapies and vaccines [Internet]. WHO; 2014. Retrieved from: https://apps.who.int/iris/bitstream/handle/10665/137590/WHO_EVD_HIS_EMP_14.1_eng.pdf
54. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M et al. Treatment of Ebola haemorrhagic fever with blood transfusions from convalescent patients. The Journal of Infectious Diseases. 1999;179(s1):S18-S23. doi:10.1086/514298
55. Interim guidance for national health authorities and blood transfusion services: Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks [Internet]. WHO; 2014. Retrieved from: https://apps.who.int/iris/bitstream/handle/10665/135591/WHO_HIS_SDS_2014.8_eng.pdf
56. PREVAIL II Writing Group. A randomized, controlled trial of ZMapp for Ebola virus infection. New England Journal of Medicine. 2016;375(15):1448-1456. DOI: http://dx.doi.org/10.1056/NEJMoa1604330
57. Investigational therapeutics for the treatment of people with Ebola virus disease [Internet]. ClinicalTrials.gov. Identifier NCT03719586 [updated 24 May 2019, accessed 26 May 2019]. Retrieved from: https://clinicaltrials.gov/ct2/show/NCT03719586
58. Years of Ebola virus disease outbreaks: Democratic Republic of Congo (DRC) (formerly Zaire) [Internet]. Cdc.gov [accessed 26 May 2019]. Retrieved from: https://www.cdc.gov/vhf/ebola/history/chronology.html
59. Khan A, Tshioko F, Heymann D, Le Guenno B, Nabeth P, Kerstiëns B et al. The reemergence of Ebola haemorrhagic fever, Democratic Republic of the Congo, 1995. The Journal of Infectious Diseases. 1999;179(s1):S76-S86. DOI: http://dx.doi.org/10.1086/514306
60. Fact sheets: Ebola virus disease [Internet]. WHO [accessed 26 May 2019]. Retrieved from: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
61. Muyembe J, Ahuka-Mundeke T, Palacios G, Wiley M, Sall A, Faye O et al. INRB statement [Internet]. The Institut National pour la Recherche Biomedicale (INRB) [unpublished manuscript, accessed 26 May 2019]. Retrieved from: https://drive.google.com/file/d/1Ih02T5z1cpqEgsBUsLtOIQhuEeb2Yh5Y/view
62. Rapid risk assessment: Outbreak of Ebola virus disease in Bas Uele province, Democratic Republic of the Congo [Internet]. European Centre for Disease Prevention and Control; 2017. https://ecdc.europa.eu/sites/portal/files/documents/RRA-Ebola-haemorrhagic-fever-DRC-May-2017.pdf
63. Ebola strikes big city in the Democratic Republic of the Congo and WHO scales up response to new threat [Internet]. WHO Regional Office for Africa [accessed 26 May 2019]. Retrieved from: https://www.afro.who.int/news/ebola-strikes-big-city-democratic-republic-congo-and-who-scales-response-new-threat
64. Bugs, Drugs and Smoke [Internet]. Geneva: World Health Organization; 2011. Retrieved from: https://www.who.int/about/bugs_drugs_smoke_chapter_7_outbreak.pdf
65. DRC approves use of Ebola vaccine [Internet]. Centre for Infectious Disease Research and Policy; 2017. Retrieved from: http://www.cidrap.umn.edu/news-perspective/2017/05/drc-approves-use-ebola-vaccine
66. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response [Internet]. WHO; 2019. https://www.who.int/csr/resources/publications/ebola/ebola-ring-vaccination-results-12-april-2019.pdf
67. Claude K, Underschultz J, Hawkes M. Ebola virus epidemic in war-torn eastern DR Congo. The Lancet. 2018;392(10156):1399-1401. DOI: http://dx.doi.org/10.1016/S0140-6736(18)32419-X
68. Branswell H. A spot of good news in an Ebola crisis: Vaccine supplies are expected to last [Internet]. STAT News. 22 Jan 2019. Retrieved from: https://www.statnews.com/2019/01/22/some-needed-good-news-on-ebola-vaccine-supplies-are-expected-to-last
69. Wawina-Bokalanga T, Vanmechelen B, Martí-Carreras J, Vergote V, Vermeire K, Muyembe-Tamfum J et al. Complete genome sequence of a new Ebola virus strain isolated during the 2017 Likati outbreak in the Democratic Republic of the Congo. Microbiology Resource Announcements. 2019;8(20). DOI: http://dx.doi.org/10.1128/mra.00360-19
70. Buceta J, Johnson K. Modeling the Ebola zoonotic dynamics: Interplay between enviroclimatic factors and bat ecology. PLOS One. 2017;12(6):e0179559. DOI: http://dx.doi.org/10.1371/journal.pone.0179559
71. DRC Ebola outbreaks: Crisis update - April 2019 [Internet]. Médecins Sans Frontières (MSF) International; 2019. Retrieved from: https://www.msf.org/drc-2018-ebola-outbreak-crisis-update
72. Congo Ebola outbreak at 'critical point' after attack on Red Cross staff [Internet]. The Guardian; 2018 Oct 5. Retrieved from: https://www.theguardian.com/global-development/2018/oct/05/democratic-republic-congo-ebola-red-cross-staff-attacked-butembo-north-kivu
73. Maxmen A. Ebola detectives race to identify hidden sources of infection as outbreak spreads. Nature. 2018;564(7735):174-175. DOI: http://dx.doi.org/10.1038/d41586-018-07618-0C
74. Strategic response plan for the Ebola virus disease outbreak in the provinces of North Kivu and Ituri (February – July 2019) [Internet]. WHO; 2019. https://www.who.int/emergencies/crises/cod/drc-ebola-srp-v20190410-en.pdf
75. RDC : le personnel chargé de la lutte anti-Ebola agressé par des habitants de Marabo [Internet]. Radiookapi; 12 Jan 2019. https://www.radiookapi.net/2019/01/12/actualite/sante/rdc-le-personnel-charge-de-la-lutte-anti-ebola-agresse-par-des-habitants
76. Ebola response failing to gain the upper hand on the epidemic [Internet]. MSF International; 2019. Retrieved from: https://www.msf.org/ebola-response-failing-gain-upper-hand-epidemic-democratic-republic-congo
77. Nuzzo J, Inglesby T. Ramping up the response to Ebola. New England Journal of Medicine. 2018;379(26):2490-2491. DOI: http://dx.doi.org/10.1056/NEJMp1814296
78. Morrison J. North Kivu’s Ebola outbreak at day 90: What is to be done? [Internet]. Center for Strategic and International Studies; 2018. Retrieved from: https://www.csis.org/analysis/north-kivus-ebola-outbreak-day-90-what-be-done
79. Aizenman N. Why does Ebola keep spreading in Congo? Here's a major clue [Internet]. NPR News. 25 Feb 2019. https://www.npr.org/sections/goatsandsoda/2019/02/25/697073103/why-does-ebola-keep-spreading-in-congo-heres-a-major-clue.
80. Ebola virus disease – Democratic Republic of the Congo: Disease outbreak news – 6 December 2018 [Internet]. WHO; 2018. https://www.who.int/csr/don/06-December-2018-ebola-drc/en
81. Blackley D, Wiley M, Ladner J, Fallah M, Lo T, Gilbert M et al. Reduced evolutionary rate in reemerged Ebola virus transmission chains. Science Advances. 2016;2(4):e1600378. DOI: http://dx.doi.org/10.1126/sciadv.1600378
82. Dokubo E, Wendland A, Mate S, Ladner J, Hamblion E, Raftery P et al. Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report. The Lancet Infectious Diseases. 2018;18(9):1015-1024. DOI: http://dx.doi.org/10.1016/S1473-3099(18)30417-1
83. Subissi L, Keita M, Mesfin S, Rezza G, Diallo B, Van Gucht S et al. Ebola virus transmission caused by persistently infected survivors of the 2014–2016 outbreak in West Africa. The Journal of Infectious Diseases. 2018;218(suppl_5):S287-S291. DOI: http://dx.doi.org/10.1093/infdis/jiy280
84. Mate S, Kugelman J, Nyenswah T, Ladner J, Wiley M, Cordier-Lassalle T et al. Molecular evidence of sexual transmission of Ebola virus. New England Journal of Medicine. 2015;373(25):2448-2454. DOI: http://dx.doi.org/10.1056/NEJMoa1509773
85. Fischer W, Brown J, Wohl D, Loftis A, Tozay S, Reeves E et al. Ebola virus ribonucleic acid detection in semen more than two years after resolution of acute Ebola virus infection. Open Forum Infectious Diseases. 2017;4(3). DOI: http://dx.doi.org/10.1093/ofid/ofx155
86. Deen G, Broutet N, Xu W, Knust B, Sesay F, McDonald S et al. Ebola RNA persistence in semen of Ebola virus disease survivors — Final Report. New England Journal of Medicine. 2017;377(15):1428-1437. DOI: http://dx.doi.org/10.1056/NEJMoa1511410